Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. (July 2016)

• Record Type: Journal Article
• Authors: Nakashima, R; Hosono, Y; Mimori, T
• Is Part Of: Lupus. Volume 25:Number 8(2016)
• Page Start: 925
• Page End: 933
• Publication Date: 2016-07
• Subjects: Polymyositis -- dermatomyositis -- clinically amyopathic dermatomyositis -- interstitial lung disease -- anti-aminoacyl tRNA synthetase antibody -- anti-synthetase syndrome -- anti-MDA5 antibody -- high resolution computed tomography -- ferritin -- enzyme-linked immunosorbent assay; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/0961203316651748
• Languages: English
• ISSNs: 0961-2033

Abstract

Anti-aminoacyl-tRNA synthetase (ARS) and anti-melanoma differentiation-associated gene 5 ( MDA5 ) antibodies are closely associated with interstitial lung disease in polymyositis and dermatomyositis. Anti-ARS-positive patients develop common clinical characteristics termed anti-synthetase syndrome and share a common clinical course, in which they respond well to initial treatment with glucocorticoids but in which disease tends to recur when glucocorticoids are tapered. Anti- MDA5 antibody is associated with rapidly progressive interstitial lung disease and poor prognosis, particularly in Asia. Therefore, intensive immunosuppressive therapy is required for anti- MDA5 -positive patients from the early phase of the disease. New enzyme-linked immunosorbent assays to detect anti-ARS and anti- MDA5 antibodies have recently been established and are suggested to be efficient and useful. These assays are expected to be widely applied in daily practice.